Bioscience trends

01 31 August 2026

DOI 10.5582/bst.2026.01219

Management of dynamic therapeutic opportunity in hepatocellular carcinoma: Preserving liver function and enabling treatment transitions

Open DOI

Jiwei Huang, Mingheng Liao, Wei Tang

Hepatocellular carcinoma (HCC) is governed by malignant progression and deterioration of the organ in which the cancer arises. Modern management has therefore outgrown static stage-to-treatment allocation. We define dynamic therapeutic o...

Read abstract

02 31 August 2026

DOI 10.5582/bst.2026.01217

Hepatic arterial infusion chemotherapy–based triplet conversion therapy for hepatocellular carcinoma with portal vein tumor thrombus: Evidence, patient selection, and surgical endpoints

Open DOI

Chaosheng Xia, Yutao He, Rongfu Hong et al.

Portal vein tumor thrombus (PVTT) is a biologically aggressive and clinically heterogeneous form of hepatocellular carcinoma (HCC). Global guidelines generally classify macrovascular invasion as advanced disease and prioritize systemic t...

Read abstract

03 31 August 2026

DOI 10.5582/bst.2026.01202

ATP6L impairs vascular stability in colorectal cancer via PDGFB/PDGFRβ signaling

Open DOI

Xiangdong Tian, Dandan Chen, Jiaqi Duo et al.

Vascular instability, characterized by impaired pericyte coverage, is a hallmark of tumor progression. ATP6L is highly expressed in colorectal cancer (CRC) tissues and promotes tumor progression by enhancing the tumor microvasculature; h...

Read abstract

04 31 August 2026

DOI 10.5582/bst.2026.01148

Immunometabolic reprogramming via GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework

Open DOI

Liqin Sun, Stephane Isnard, Haipeng Zhu et al.

Antiretroviral therapy (ART) has transformed HIV infection into a manageable chronic condition, but pathological weight gain, adipose dysfunction, and persistent inflammation are increasingly prevalent among aging people with HIV (PWH). ...

Read abstract

05 31 August 2026

DOI 10.5582/bst.2026.01126

Underrecognized cardiovascular complications after hepatectomy: population-level mortality burden from a multicentre population-attributable fraction (PAF) analysis

Open DOI

Junlong Dai, Zhancheng Qiu, Jimmy Che-To Lai et al.

Postoperative complications remain major determinants of outcomes after hepatectomy for hepatocellular carcinoma (HCC), but whether complications that prolong hospitalization are also those that contribute most to mortality remains uncle...

Read abstract

06 31 August 2026

DOI 10.5582/bst.2026.01104

Comparison of current global guidelines and consensus on the management of patients with cholangiocarcinoma: A 2026 update

Open DOI

Enyang He, Yulong Cai, Xianze Xiong et al.

Cholangiocarcinoma (CCA) is a highly aggressive, molecularly heterogeneous biliary tract malignancy and the second most common primary liver cancer, and it has an increasing global incidence and persistently poor prognosis. Recent update...

Read abstract

07 30 April 2026

DOI 10.5582/bst.2025.01335

Comparative safety and efficacy of BIC/FTC/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort study

Open DOI

Liqin Sun, Yuxin Jiang, Stephane Isnard et al.

While bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir plus lamivudine (DTG+3TC) are first-line regimens for treatment-naive people with HIV (PWH), long-term real-world head-to-head comparisons of their meta...

Read abstract

08 30 April 2026

DOI 10.5582/bst.2026.01043

Modeling of the hepatitis B virus life cycle and the efficacy of antivirals in human iPSC-derived hepatic organoids

Open DOI

Tanbin Liu, Junming Xu, Xiaoni Chen et al.

Hepatitis B virus (HBV) infection remains a major global health burden, affecting approximately 296 million people worldwide, and yet progress in mechanistic studies and development of antivirals has been limited by the lack of physiolog...

Read abstract

09 30 April 2026

DOI 10.5582/bst.2026.01046

Biallelic inactivation of EXT1 in patient-derived iPSCs confirms the "Two-hit" hypothesis in hereditary multiple osteochondromas

Open DOI

Yali Yang, Zhenzhong Han, Guowei Li et al.

Hereditary Multiple Osteochondromas (HMO) is a rare autosomal dominant skeletal disorder caused by heterozygous loss-of-function mutations in EXT1 or EXT2, which encode glycosyltransferases essential for heparan sulfate (HS) biosynthesis...

Read abstract

10 30 April 2026

DOI 10.5582/bst.2026.01032

Characteristics and management of constitutional indocyanine green excretory defect

Open DOI

Jiaao Wang, Ziqi Hou, Jun Ji et al.

Indocyanine green (ICG) test is a popular and widely implied assessment of hepatic functional reserve (HFR) due to its safety and efficiency. However, as the application of ICG expanded, an exceedingly rare disorder, the constitutional I...

Read abstract